| 產(chǎn)品編號(hào) |
bsk11155 |
| 英文名稱 |
Human Apolipoprotein A-1/ApoA1 ELISA Kit
|
| 中文名稱 |
人載脂蛋白A1酶聯(lián)免疫試劑盒 |
| 別 名 |
Apo-AI; ApoA I; ApoA-I; APOA1_HUMAN; Apolipoprotein A-I(1-242); Apolipoprotein A1; Apolipoprotein A 1; Apolipoprotein AI; Apolipoprotein A I; Brp14; Ltw1; Lvtw1; Sep1; Sep2. |
| 種 屬 |
Human |
| 線性范圍 |
3.12 - 200 ng/mL |
| 應(yīng)用范圍 |
S/P/CC |
| 檢測限 |
2 ng/mL |
| 適用樣品基質(zhì) |
cell culture supernates, serum, and plasma. |
| 保存條件 |
Store at 4°C for 6 months, at -20°C for 12 months. Avoid multiple freeze-thaw cycles (Shipped with wet ice.). |
| 注意事項(xiàng) |
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 產(chǎn)品介紹 |
Apolipoprotein A I promotes cholesterol efflux from tissues to the liver for excretion. Apolipoprotein A I is the major protein component of high density lipoprotein (HDL) in the plasma. Synthesized in the liver and small intestine, it consists of two identical chains of 77 amino acids; an 18 amino acid signal peptide is removed co-translationally and a 6 amino acid propeptide is cleaved post-translationally. Apolipoprotein A I is a cofactor for lecithin cholesterolacyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. Defects in the Apolipoprotein A I gene are associated with HDL deficiency and Tangier disease. The therapeutic potential of apoA-I has been recently assessed in patients with acute coronary syndromes, using a recombinant form of a naturally occurring variant of apoA-I. The availability of recombinant normal apoA-I should facilitate further investigation into the potential usefulness of apoA-I in preventing atherosclerotic vascular diseases.
|
|
|
